Rigenerand engages CRO Coresearch for Phase I gene therapy study in pancreatic cancer, executive says

Rigenerand
The Phase I will focus on finding the optimal dose of RR001 and evaluating the treatment’s efficacy profile in pancreatic cancer. Credit: NIH Image Gallery.